A retrospective study assessing impact of HMR mutations on treatment success and outcome in int-1 risk intermediate-1 risk myelofibrosis patients treated with Ruxolitinib

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

17 Jun 2022 Results of sub-analysis of the RUX-MF and other study distinguishing RUX-treated patients at higher risk of COVID-19 and assessing prognostic factors for OS, presented at the 27th Congress of the European Haematology Association
05 Aug 2021 New trial record
17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com